Stroke Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Stroke Northumbria, Northumbria Healthcare NHS Foundation Trust, North Tyneside, UK.
Health Technol Assess. 2020 Oct;24(54):1-232. doi: 10.3310/hta24540.
Loss of arm function is common after stroke. Robot-assisted training may improve arm outcomes.
The objectives were to determine the clinical effectiveness and cost-effectiveness of robot-assisted training, compared with an enhanced upper limb therapy programme and with usual care.
This was a pragmatic, observer-blind, multicentre randomised controlled trial with embedded health economic and process evaluations.
The trial was set in four NHS trial centres.
Patients with moderate or severe upper limb functional limitation, between 1 week and 5 years following first stroke, were recruited.
Robot-assisted training using the Massachusetts Institute of Technology-Manus robotic gym system (InMotion commercial version, Interactive Motion Technologies, Inc., Watertown, MA, USA), an enhanced upper limb therapy programme comprising repetitive functional task practice, and usual care.
The primary outcome was upper limb functional recovery 'success' (assessed using the Action Research Arm Test) at 3 months. Secondary outcomes at 3 and 6 months were the Action Research Arm Test results, upper limb impairment (measured using the Fugl-Meyer Assessment), activities of daily living (measured using the Barthel Activities of Daily Living Index), quality of life (measured using the Stroke Impact Scale), resource use costs and quality-adjusted life-years.
A total of 770 participants were randomised (robot-assisted training, = 257; enhanced upper limb therapy, = 259; usual care, = 254). Upper limb functional recovery 'success' was achieved in the robot-assisted training [103/232 (44%)], enhanced upper limb therapy [118/234 (50%)] and usual care groups [85/203 (42%)]. These differences were not statistically significant; the adjusted odds ratios were as follows: robot-assisted training versus usual care, 1.2 (98.33% confidence interval 0.7 to 2.0); enhanced upper limb therapy versus usual care, 1.5 (98.33% confidence interval 0.9 to 2.5); and robot-assisted training versus enhanced upper limb therapy, 0.8 (98.33% confidence interval 0.5 to 1.3). The robot-assisted training group had less upper limb impairment (as measured by the Fugl-Meyer Assessment motor subscale) than the usual care group at 3 and 6 months. The enhanced upper limb therapy group had less upper limb impairment (as measured by the Fugl-Meyer Assessment motor subscale), better mobility (as measured by the Stroke Impact Scale mobility domain) and better performance in activities of daily living (as measured by the Stroke Impact Scale activities of daily living domain) than the usual care group, at 3 months. The robot-assisted training group performed less well in activities of daily living (as measured by the Stroke Impact Scale activities of daily living domain) than the enhanced upper limb therapy group at 3 months. No other differences were clinically important and statistically significant. Participants found the robot-assisted training and the enhanced upper limb therapy group programmes acceptable. Neither intervention, as provided in this trial, was cost-effective at current National Institute for Health and Care Excellence willingness-to-pay thresholds for a quality-adjusted life-year.
Robot-assisted training did not improve upper limb function compared with usual care. Although robot-assisted training improved upper limb impairment, this did not translate into improvements in other outcomes. Enhanced upper limb therapy resulted in potentially important improvements on upper limb impairment, in performance of activities of daily living, and in mobility. Neither intervention was cost-effective.
Further research is needed to find ways to translate the improvements in upper limb impairment seen with robot-assisted training into improvements in upper limb function and activities of daily living. Innovations to make rehabilitation programmes more cost-effective are required.
Pragmatic inclusion criteria led to the recruitment of some participants with little prospect of recovery. The attrition rate was higher in the usual care group than in the robot-assisted training or enhanced upper limb therapy groups, and differential attrition is a potential source of bias. Obtaining accurate information about the usual care that participants were receiving was a challenge.
Current Controlled Trials ISRCTN69371850.
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 24, No. 54. See the NIHR Journals Library website for further project information.
中风后手臂功能丧失较为常见。机器人辅助训练可能改善手臂预后。
旨在确定机器人辅助训练与强化上肢治疗方案和常规护理相比的临床效果和成本效益。
这是一项实用性、观察者盲法、多中心随机对照试验,具有嵌入式健康经济和过程评估。
试验在四家 NHS 试验中心进行。
招募了患有中度或重度上肢功能受限、中风后 1 周至 5 年的患者。
使用马萨诸塞州理工学院-Manus 机器人健身房系统(InMotion 商业版,Interactive Motion Technologies,Inc.,沃特敦,MA,USA)进行机器人辅助训练、包括重复功能任务练习的强化上肢治疗方案和常规护理。
主要结果是 3 个月时上肢功能恢复“成功”(使用动作研究上肢测试评估)。次要结果在 3 个月和 6 个月时是动作研究上肢测试结果、上肢损伤(使用 Fugl-Meyer 评估测量)、日常生活活动(使用 Barthel 日常生活活动指数测量)、生活质量(使用中风影响量表测量)、资源使用成本和质量调整生命年。
共有 770 名参与者被随机分组(机器人辅助训练组,n=257;强化上肢治疗组,n=259;常规护理组,n=254)。机器人辅助训练组上肢功能恢复“成功”的比例为 44%(103/232),强化上肢治疗组为 50%(118/234),常规护理组为 42%(85/203)。这些差异无统计学意义;调整后的优势比如下:机器人辅助训练与常规护理相比,1.2(98.33%置信区间 0.7 至 2.0);强化上肢治疗与常规护理相比,1.5(98.33%置信区间 0.9 至 2.5);机器人辅助训练与强化上肢治疗相比,0.8(98.33%置信区间 0.5 至 1.3)。与常规护理组相比,机器人辅助训练组在 3 个月和 6 个月时上肢损伤(Fugl-Meyer 评估运动子量表)较少。强化上肢治疗组在 3 个月时上肢损伤(Fugl-Meyer 评估运动子量表)较少,活动能力(中风影响量表活动能力领域)和日常生活活动(中风影响量表日常生活活动领域)更好,与常规护理组相比。机器人辅助训练组在 3 个月时的日常生活活动(中风影响量表日常生活活动领域)表现不如强化上肢治疗组。其他方面没有明显的临床意义和统计学意义。参与者发现机器人辅助训练和强化上肢治疗组的方案可接受。在当前国家卫生与保健卓越研究所(National Institute for Health and Care Excellence)对质量调整生命年的支付意愿阈值下,这两种干预措施都没有成本效益。
与常规护理相比,机器人辅助训练并未改善上肢功能。尽管机器人辅助训练改善了上肢损伤,但这并没有转化为其他结果的改善。强化上肢治疗在上肢损伤、日常生活活动和活动能力方面产生了潜在的重要改善。这两种干预措施都不具有成本效益。
需要进一步研究如何将机器人辅助训练中看到的上肢损伤改善转化为上肢功能和日常生活活动的改善。需要创新使康复方案更具成本效益。
实用的纳入标准导致一些恢复前景不大的参与者被招募。常规护理组的失访率高于机器人辅助训练组或强化上肢治疗组,失访的差异可能是一个潜在的偏倚源。准确获取参与者接受的常规护理信息是一个挑战。
当前对照试验 ISRCTN69371850。
该项目由英国国家卫生研究院(NIHR)健康技术评估计划资助,将全文发表在 ; 第 24 卷,第 54 期。有关该项目的更多信息,请访问 NIHR 期刊库网站。